The upregulation of TIM-3, especially when combined with PD-1, signifies exhaustion of TILs and is associated with impaired anti-tumor responses across different cancers, including melanoma, NSCLC, and diffuse large B-cell lymphoma (DLBCL) [74,75,76]. Here, PDCD1 is linked to melanoma.